Access expired on Friday, May 27, 2022
This content was originally shared by a registered user, but access has expired. Create a free account to gain permanent access to all PracticeUpdate content.
Already Have An Account? Log in Now
featured
Minimal Residual Disease and Survival Outcomes in Patients With Multiple Myeloma After ASCT and Maintenance With Lenalidomide
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Journal of Clinical Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Minimal Residual Disease After Autologous Stem-Cell Transplant for Patients With Myeloma: Prognostic Significance and the Impact of Lenalidomide Maintenance and Molecular Risk
J. Clin. Oncol 2022 Apr 04;[EPub Ahead of Print], RM de Tute, C Pawlyn, DA Cairns, FE Davies, T Menzies, A Rawstron, JR Jones, A Hockaday, R Henderson, G Cook, MT Drayson, MW Jenner, MF Kaiser, WM Gregory, GJ Morgan, GH Jackson, RG OwenFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.